Rathbones Group PLC Raises Stock Holdings in Novo Nordisk A/S $NVO

Rathbones Group PLC increased its position in Novo Nordisk A/S (NYSE:NVO) by 79.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,138 shares of the company’s stock after acquiring an additional 32,270 shares during the period. Rathbones Group PLC’s holdings in Novo Nordisk A/S were worth $3,721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S in the 3rd quarter worth $25,000. WealthCollab LLC raised its stake in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust purchased a new position in Novo Nordisk A/S in the 4th quarter worth $28,000. Maseco LLP purchased a new position in Novo Nordisk A/S in the 4th quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in Novo Nordisk A/S in the 4th quarter worth $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $44.91 on Friday. The stock has a 50-day simple moving average of $40.29 and a two-hundred day simple moving average of $46.46. The firm has a market capitalization of $200.52 billion, a P/E ratio of 10.54, a PEG ratio of 3.96 and a beta of 0.77. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.46 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on NVO shares. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Finally, Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $65.56.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: European regulators recommended approval of Novo Nordisk’s Wegovy 7.2 mg pen, with trial data showing up to 20.7% mean weight loss, strengthening the company’s obesity-drug pipeline and supporting future EU sales. Article Title
• Positive Sentiment: The CHMP also recommended approval for Novo Nordisk’s Wegovy pill, potentially making it the first oral GLP-1 obesity drug in the EU and broadening the company’s treatment options. Article Title
• Positive Sentiment: Reuters reported Novo is using AI to speed drug development and expand its role in India, which could help it bring new products to market faster and regain momentum in obesity. Article Title
• Neutral Sentiment: Industry chatter about Lilly’s obesity-drug breakthrough and reports that both Lilly and Novo drugs may have cancer-prevention benefits highlight strong demand in the class, but also underscore intensifying competition and a larger long-term market. Article Title
• Negative Sentiment: Eli Lilly’s retatrutide posted about 28% weight loss in late-stage testing, setting a new benchmark that increases pressure on Novo Nordisk to keep innovating in obesity and GLP-1 therapies. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.